Research progress in production of lipstatinfermentation

doi:10.16085/j.issn.1000-6613.2020-1653

Abstract

Abstract:

Lipstatin is a β-lactone molecule which controls the digestive activity of pancreatic lipases and thus controls the absorption of fat in the small intestine. Lipstatin is supposed to inhibit the catalytic activity of pancreatic lipase by acylation of the serine residue present in the active site. A binding study suggests that one molecule of lipstatin binds with one molecule of lipase. Lipstatin is a natural product produced from Streptomyces toxytricini. The chemical structure is introduced,and the current application situation is reviewed. The progress in production of lipstatin fermentation is presented with a discussion on existing problems. Technology of metabolic engineering used in fermentation is introduced especially.The mechanism of lipstatin biosynthesis in bacteria is not yet clear, however acyl-coenzyme A carboxylase (ACCase) complex is playing key role in lipstatin biosynthesis. Furthermore, prospect for future research is proposed.

Key words: lipstatin, fermentation, metabolic engineering, Streptomyces toxytricini

摘要：

利普司他汀（lipstatin）是一种β-内酯分子，能选择性抑制胰脂肪酶的活性，从而减少小肠脂肪的吸收。分析表明，一个利普司他汀分子与一个脂肪酶分子结合，通过活性部位丝氨酸残基的酰化来抑制胰脂肪酶的催化活性。利普司他汀由毒三链霉菌（Streptomyces toxytricini，简称S. toxytricini）生产的一种天然产物。本文综述了利普司他汀的结构特点，分析了利普司他汀市场应用现状，着重论述了发酵法生产利普司他汀的研究进展；提出生物合成利普司他汀的机制尚不清楚，但酰基辅酶A羧化酶（ACCase）复合物在利普司他汀生物合成中起着关键作用。最后，指出当前存在的问题并对代谢工程在利普司他汀产生菌发酵中的应用进行概述，对今后的研究趋势进行了展望。

关键词: 利普司他汀, 发酵, 代谢工程, 毒三素链霉菌

CLC Number:

TQ460

LI Ling, YU Yong, HU Yonghong. Research progress in production of lipstatinfermentation[J]. Chemical Industry and Engineering Progress, 2021, 40(4): 2251-2257.

李玲, 于泳, 胡永红. 发酵法生产利普司他汀的研究进展[J]. 化工进展, 2021, 40(4): 2251-2257.

Figures/Tables 4

References 48

1	HOCHULI E，KUPFER E，MAURER R，et al. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytriciniⅡ.Chemistry and structure elucidation[J]. J. Antibiot., 1987, 40(8): 1086-1091.
2	WEIBEL E K, HADVARY P, HOCHULI E. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. Ⅰ. Producing organism, fermentation, isolation and biological activity[J]. Antibiot., 1987, 40(8): 1081-1085.
3	CARTER R, MOURALIDARANE A, RAY S, et al. Recent advancements in drug treatment of obesity[J]. Clin. Med., 2012, 12(5): 456-460.
4	MELIA A T, ZHI J, ZELASKO R, et al. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers[J]. Eur. J. Clin. Pharmacol., 1998, 54(9): 773-775.
5	AHN SM, KIM H, JI E, et al. The effect of orlistat on weight reduction in obese and overweight Korean patients[J]. Arch. Pharm. Res., 2014, 37(4): 512-519.
6	NG M, FLEMING T, ROBINSON M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980—2013：a systematic analysis for the global burden of disease study 2013[J]. Lancet, 2016, 384(9945）:766-784.
7	DAVIDSON M H, HAUPTMAN J, DIGIROLAMO M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat[J]. The Journal of the American Medical Association, 1999, 281(3): 235-243.
8	LIU T T, LIU X T, CHEN Q X, et al. Lipase inhibitors for obesity: a review[J]. Biomed. Pharmacother., 2020, 108: 110314.
9	KUMAR P, DUBEY K K. Current trends and future prospects of lipstatin: a lipase inhibitor and pro-drug for obesity[J]. RSC Adv., 2015, 5: 86954-86966.
10	CHAKRAVARTY B, GU Z, CHIRALA S S, et al. Human fatty acid synthase: structure and substrate selectivity of the thioesterase domain[J]. Proc. Natl. Acad. Sci. USA, 2004, 101(44): 15567-15572.
11	AGOSTINI M, ALMEIDA L Y, BASTOS D C, et al. The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas[J]. Mol. Cancer Ther., 2014, 13(3): 585-595.
12	SEGUIN F, CARVALHO M A, BASTOS D C, et al. The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas[J]. British Journal of Cancer, 2012, 107(6): 977-987.
13	KNOWLES LM, YANG C, OSTERMAN A, et al. Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4[J]. J. Biol. Chem., 2008, 283(46): 31378-31384.
14	KANT S, KUMAR A, SINGH S M. Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules[J]. Biochim. Biophys. Acta, 2012, 1820(11): 1764-1773.
15	XIAO X, LIU H, LI X. Orlistat treatment induces apoptosis and arrests cell cycle in HSC-3 oral cancer cells[J]. Microb. Pathogenesis, 2017, 112: 15-19.
16	ZHANG C, SHENG L, YUAN M, et.al. Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met[J]. Toxicol. Appl. Pharmacol., 2020, 392: 114918.
17	HAHN J, SEEBER F, KOLODZIEJ H, et al. High sensitivity of Giardia duodenalis to tetrahydrolipstatin (orlistat） in vitro[J]. PLoS One, 2013, 8(8): 1-10.
18	吴宝, 许国磊, 谢相智, 等. 奥利司他联合瑞舒伐他汀治疗单纯性肥胖伴高脂血症患者的疗效分析[J]. 中国循证心血管医学杂志, 2017, 9(7): 845⁃847.
	WU Bao, XU Guolei, XIE Xiangzhi, et al. Efficacy of orlistat combined with rosuvastatin in the treatment of simple obesity with hyperlipidemia[J] . Chin. J. Evid. Based Cardiovasc. Med., 2017, 9(7): 845⁃847.
19	SULEIMAN J B, NNA V U, ZAKARIA Z, et al. Obesity-induced testicular oxidative stress, inflammation and apoptosis: protective and therapeutic effects of orlistat[J]. Reprod. Toxicol., 2020, 95:113-122.
20	BRAY G A, GREENWAY F L. Current and potential drugs for treatment of obesity[J] . Endocr. Rev., 1999, 20(6): 805 -875.
21	FINER N, JAMES W P, KOPELMAN P G, et al. One year treatment of obesity: arandomized, doubleblind, placebo controlled, multicenter study of orlistat, a gastrointestinal lipase inhibitor[ J] . Int. J. Obes. Relat. Metab. Disord., 2000, 24(3): 306 -313.
22	PAUL H, ERICH H, ERNST K, et al. Leucine derivatives: EP129748[P]. 1985-01-02.
23	VARGA I, GONDOVA B, GAJDOSIKOVA J, et a1. The strain streptomyces·toxytricini lipstatin producing microorganism and preparation of lipstatin with inscribed strain: WO2007008263A2[P]. 2007-07-12.
24	GASPARIC A, SVAGEL N B, RASPOR P, et al. Frmentative production of lipstatin: EP1860194A1[P]. 2007-11-28.
25	FUJS S, KUSCER E, PETKOVIC H, et a1. Process for production of 1ipstatin and microorganisms therefore: WO2010000839A1[P]. 2010-01-07.
26	KUMAR M S, VERMA V, SONI S, et al. Identification and process development for enhanced production of lipstatin from Streptomyces toxytricini (NRRL 15443) and further downstream processing[J]. Adv. Biol. Tech., 2011, 11: 6-11.
27	LUTHRA U, KUMAR H, DUBEY R C. Mutagenesis of The lipstatin producer Streptomyces toxytricini ATCC 19813[J]. J. Biotechnol. Lett., 2013, 4: 68-71.
28	LUTHRA U, KUMAR H, KULSHRESHTHA N, et al. Medium optimization for the production of lipstatin by Streptomyces toxytricini using full factorial design of experiment[J]. Nat. Sci., 2013, 11(7): 73-76.
29	KUMAR P, DUBEY K K. Modulation of fatty acid metabolism and tricarboxylic acid cycle to enhance the lipstatin production through medium engineering in Streptomyces toxytricini[J]. Bioresour. Technol., 2016, 213: 64-68.
30	KUMAR P, DUBEY K K. Mycelium transformation of Streptomyces toxytricini into pellet: role of culture conditions and kinetics[J]. Bioresour. Technol., 2017, 228: 339-347.
31	KUMAR P, DUBEY K K. Implication of mutagenesis and precursor supplementation towards the enhancement of lipstatin (an antiobesity agent) biosynthesis through submerged fermentation using Streptomyces toxytricini[J]. 3 Biotech., 2018, 8(1): 29-37.
32	KHUSHBOO, PINKI, KUMAR Punit, et al. Enhanced production of lipstatin from mutant of Streptomyces toxytricini and fed-batch strategies under submerged fermentation[J]. 3 Biotech., 2020, 10(4): 151.
33	王栋海. Lipstatin的开发与研究[D]. 上海: 上海师范大学, 2004.
	WANG D H. The research and development of lipstatin[D]. Shanghai: Shanghai Normal University, 2004.
34	韩俊茹, 史毓芳, 陈金龙, 等. 利普司他汀发酵工艺研究[J]. 浙江工业大学学报, 2006, 34(2): 141-144.
	HAN Junru, SHI Yufang, CHEN Jinlong, et al. Study on the fermentation process of lipstatin[J]. Journal of Zhejiang University of Technology, 2006, 34(2): 141-144.
35	ZHU T, WANG L, WANG W, et al. Enhanced production of lipstatin from Streptomyces toxytricini by optimizing fermentation conditions and medium[J]. J Gen. Appl. Microbiol., 2014, 60(3): 106-111.
36	王永青. Lipstatin发酵工艺的优化研究[D]. 青岛: 中国海洋大学, 2013.
	WANG Y Q. Study on the optimization of lipstatin fermentation[D]. Qingdao: Ocean University of China, 2013.
37	孙菲. 脂肪酶抑制剂lipstatin 的发酵罐发酵工艺优化[J]. 食品与发酵工业, 2014, 40(9): 63-67.
	SUN Fei. Studies on the process optimization of lipstatin: an pancrelipase inhibitor in small fermentor[J]. Food Ferment. Ind., 2014, 40(9): 63-67.
38	黄娟, 陈正杰, 冯军, 等. 紫外和微波相结合诱变选育lipstatin 产生菌[J]. 中国医药工业杂志, 2006, 37(1): 12-14.
	HUANG Juan, CHEN Zhengjie, FENG Jun, et al. Induced mutagenesis of lipstatin producing strain by ultraviolet ray and microwave[J]. Chin. J. Pharm., 2006, 37(1): 12-14.
39	刘顺娜, 沈晓放, 杨松柏, 等. 利普司他汀产生菌的菌种选育及培养基优化[J]. 中国医药工业杂志, 2017, 48(7): 1006-1011.
	LIU Shunna, SHEN Xiaofang, YANG Songbai, et al. Mutation breeding and optimization of fermentation medium of lipstatin producing strain[J]. Chin. J. Pharm., 2017, 48(7): 1006-1011.
40	陈洲琴, 张祝兰, 杨煌建, 等. 产利普斯他汀菌株Streptomyces toxytricini FIM-17-16发酵条件的优化[J]. 中国抗生素杂志, 2020(8): 769-774.
	CHEN Z Q, ZHANG Z L, YANG H J,et al. Optimization of fermentation conditions for Streptomyces toxytricini FIM-17-16[J]. J. Chin. Antibiotics, 2020(8): 769-774.
41	EISENREICH W, KUPFER E, WEBER W, et al. Tracer studies with crude U-13C-lipid mixtures[J]. J. Biol. Chem., 1997, 272(2): 867-874.
42	BODKIN J A, HUMPHRIES E J, MC L M. The total synthesis of (-)-tetrahydrolipstatin[J]. Tetrahedron. Lett., 2003, 44(14): 2869-2872.
43	BACHER A, GOESE M, EISENREICH W, et al. Biosynthesis of lipstatin. Incorporation of multiply deuterium-labeled(5Z,8Z)-etradeea- 5,8-dienoic acid and octanoic acid[J]. Org. Chem., 2001, 66(13): 4673-4678.
44	BACHER A, SCHUHR C A, EISENREICH W, et al. Biosynthetic precursors of the lipase inhibitor lipstatin[J]. Org. Chem., 2002, 67(7): 2257-2262.
45	DEMIREV A V, KHANAL A, SEDAI B R, et al. The role of acyl-coenzyme A carboxylase complex in lipstatin biosynthesis of Streptomyces toxytricini[J]. Appl. Microbiol. Biotechnol., 2010, 87(3): 1129-1139.
46	DEMIREV A V, ANAMIKA Khanal, NGUYEN P K H, et al. Biochemical characteristization of propionyl-coenzyme a carboxylase complex of Streptomyces toxytricini[J]. J. Microbiol., 2011, 49: 407-412.
47	BAI T L, ZHANG D Z, LIN S J, et al. Operon for biosynthesis of lipstatin, the beta-lactone inhibitor of human pancreatic lipase[J]. Appl. Environ. Microbiol., 2014, 80(24): 7473-7483.
48	ZHANG D Z, ZHANG F, LIU W. A KAS-Ⅲ Heterodimer in lipstatin biosynthesis nondecarboxylatively condenses C₈ and C₁₄ fatty acyl-CoA substrates by a variable mechanism during the establishment of a C₂₂ aliphatic skeleton[J]. Amhem. Soc., 2019, 141(9): 3993-4001.

菌株	育种、优化方法	效价 /mg·L^-1	研究团队	年份
S.toxytricini NRRL 15443		6.23	Paul等^[22]	1985
S.toxytricini NRRL 15443		43.17	Weibel等^[2]	1987
S.toxytricini CCM 7349	70L发酵罐补料发酵，约34h补加亚油酸、L-亮氨酸混合溶液	3290	Varga等^[23]	2007
S.toxytricini	补料添加0.3%亚油酸、1%豆油	4773	Gasparic等^[24]	2007
S.toxytricini	培养20h后补加亚油酸和L-亮氨酸，控制亚油酸体积分数0.3%~0.5%	4400	Fujs等^[25]	2010
S.toxytricini NRRL 15443	Plackett-Burman法优化发酵种子、发酵培养基	1980	Kumar等^[26]	2011
S.toxytricini ATCC 19813	UV和NTG联合诱变，全因子试验设计优化发酵培养条件，大豆粉35g/L和豆油25g/L	3290	Luthra等^[27-28]	2013
S.toxytricini NRRL B-5426	调节碳氮比例、补充金属辅因子、维生素、TCA循环中间产物，有机酸和NADH	2242.63	Kumar等^[29]	2016
S.toxytricini NRRL B-5426	紫外、甲磺酸乙酯、甲基甲烷磺酸盐和NTG复合诱变结合前体物添加	2387	Kumar等^[31]	2018
S.toxytricini srn7	添加前体：亚油酸0.02～0.1mg/g，油酸0.02～0.15mg/g，L-亮氨酸1.5%，大豆粉10%	5886	Khushboo等^[32]	2020
S.toxytricini HCCB-2	紫外和微波复合诱变，培养条件优化	663	王栋海^[33]	2004
S.toxytricini XC-lp-69	紫外和微波复合诱变，补料发酵	1400	韩俊如等^[34]	2006
S.toxytricini SIPI-UN-21	紫外、NTG复合诱变，培养条件优化	3.25倍	黄娟等^[38]	2006
S.toxytricini	正交设计优化发酵培养基，补料油酸/辛酸补料、L-亮氨酸和豆油	1.2倍	王永青^[36]	2013
S.toxytricini zjut011	正交试验法，添加前体L-亮氨酸，首次发现二价阳离子Mg²⁺、Co²⁺和Zn²⁺对提高效价有显著作用	4208	Zhu等^[35]	2014
S.toxytricini FIM-1015	考察溶氧和剪切力因素，10L发酵罐补料发酵	6446	孙菲^[37]	2014
S.toxytricini LIPS-352	紫外-微波复合诱变，添加前体葵花籽油，Box-Behnken设计优化	8122.9	刘顺娜等^[39]	2017
S.toxytricini FIM-17-16	发酵条件优化	9667	陈洲琴等^[40]	2020

菌株	育种、优化方法	效价 /mg·L^-1	研究团队	年份
S.toxytricini NRRL 15443		6.23	Paul等^[22]	1985
S.toxytricini NRRL 15443		43.17	Weibel等^[2]	1987
S.toxytricini CCM 7349	70L发酵罐补料发酵，约34h补加亚油酸、L-亮氨酸混合溶液	3290	Varga等^[23]	2007
S.toxytricini	补料添加0.3%亚油酸、1%豆油	4773	Gasparic等^[24]	2007
S.toxytricini	培养20h后补加亚油酸和L-亮氨酸，控制亚油酸体积分数0.3%~0.5%	4400	Fujs等^[25]	2010
S.toxytricini NRRL 15443	Plackett-Burman法优化发酵种子、发酵培养基	1980	Kumar等^[26]	2011
S.toxytricini ATCC 19813	UV和NTG联合诱变，全因子试验设计优化发酵培养条件，大豆粉35g/L和豆油25g/L	3290	Luthra等^[27-28]	2013
S.toxytricini NRRL B-5426	调节碳氮比例、补充金属辅因子、维生素、TCA循环中间产物，有机酸和NADH	2242.63	Kumar等^[29]	2016
S.toxytricini NRRL B-5426	紫外、甲磺酸乙酯、甲基甲烷磺酸盐和NTG复合诱变结合前体物添加	2387	Kumar等^[31]	2018
S.toxytricini srn7	添加前体：亚油酸0.02～0.1mg/g，油酸0.02～0.15mg/g，L-亮氨酸1.5%，大豆粉10%	5886	Khushboo等^[32]	2020
S.toxytricini HCCB-2	紫外和微波复合诱变，培养条件优化	663	王栋海^[33]	2004
S.toxytricini XC-lp-69	紫外和微波复合诱变，补料发酵	1400	韩俊如等^[34]	2006
S.toxytricini SIPI-UN-21	紫外、NTG复合诱变，培养条件优化	3.25倍	黄娟等^[38]	2006
S.toxytricini	正交设计优化发酵培养基，补料油酸/辛酸补料、L-亮氨酸和豆油	1.2倍	王永青^[36]	2013
S.toxytricini zjut011	正交试验法，添加前体L-亮氨酸，首次发现二价阳离子Mg²⁺、Co²⁺和Zn²⁺对提高效价有显著作用	4208	Zhu等^[35]	2014
S.toxytricini FIM-1015	考察溶氧和剪切力因素，10L发酵罐补料发酵	6446	孙菲^[37]	2014
S.toxytricini LIPS-352	紫外-微波复合诱变，添加前体葵花籽油，Box-Behnken设计优化	8122.9	刘顺娜等^[39]	2017
S.toxytricini FIM-17-16	发酵条件优化	9667	陈洲琴等^[40]	2020

[1]	WANG Xueting, GU Xia, XU Xianbao, ZHAO Lei, XUE Gang, LI Xiang. Effectiveness of hydrothermal pretreatment on valeric acid production during food waste fermentation [J]. Chemical Industry and Engineering Progress, 2023, 42(9): 4994-5002.
[2]	QIN Kai, YANG Shilin, LI Jun, CHU Zhenyu, BO Cuimei. A Kalman filter algorithm-based high precision detection method for glucoamylase biosensors [J]. Chemical Industry and Engineering Progress, 2023, 42(6): 3177-3186.
[3]	HUANG Yue, ZHAO Lixin, YAO Zonglu, YU Jiadong, LI Zaixing, SHEN Ruixia, AN Kemeng, HUANG Yali. Research progress in directed bioconversion of lactic acid and acetic acid from wood lignocellulosic wastes [J]. Chemical Industry and Engineering Progress, 2023, 42(5): 2691-2701.
[4]	LI Wanqi, YANG Fengjuan, JIA Dechen, JIANG Weihong, GU Yang. Biological utilization and conversion of syngas [J]. Chemical Industry and Engineering Progress, 2023, 42(1): 73-85.
[5]	TAO Yuxuan, GUO Liang, GAO Cong, SONG Wei, CHEN Xiulai. Progress in metabolic engineering of microorganisms for CO₂ fixation [J]. Chemical Industry and Engineering Progress, 2023, 42(1): 40-52.
[6]	WANG Chuandong, ZHANG Junqi, LIU Dingyuan, MA Yuanyuan, LI Feng, SONG Hao. Co-utilization of xylose and glucose to produce chemicals by microorganisms [J]. Chemical Industry and Engineering Progress, 2023, 42(1): 354-372.
[7]	GUO Feng, ZHANG Shangjie, JIANG Yujia, JIANG Wankui, XIN Fengxue, ZHANG Wenming, JIANG Min. Biotransformation of one-carbon resources by yeast [J]. Chemical Industry and Engineering Progress, 2023, 42(1): 30-39.
[8]	WU Hanzhu, SI Zhihao, QIN Peiyong. Current progress of in situ bioethanol separation technology [J]. Chemical Industry and Engineering Progress, 2022, 41(3): 1318-1329.
[9]	TANG Wenxiu, WANG Xueming, GUO Liang, JI Lihao, GAO Cong, CHEN Xiulai, LIU Liming. Metabolic engineering of Escherichia coli to produce succinic acid [J]. Chemical Industry and Engineering Progress, 2022, 41(2): 938-950.
[10]	QI Zhenhua, ZHOU Rong, BAI Yanan, LI Yuqin, TANG Yufang. Fermentation wastewater treatment and high-quality protein production by Chlorella pyrenoidosa under fed-batch mode [J]. Chemical Industry and Engineering Progress, 2022, 41(12): 6733-6743.
[11]	ZHANG Qiang, CHEN Shiyang. Effect of oxygen-assisted hydrothermal pretreatment on fermentation of corn stover to ethanol [J]. Chemical Industry and Engineering Progress, 2022, 41(1): 161-165.
[12]	GAO Hao, LU Jiasheng, ZHANG Wenming, DONG Weiliang, FANG Yan, YU Ziyi, XIN Fengxue, JIANG Min. Application of material-mediated cell immobilization technology in biological fermentation [J]. Chemical Industry and Engineering Progress, 2021, 40(7): 3923-3931.
[13]	CAI Di, LI Shufeng, SI Zhihao, QIN Peiyong, TAN Tianwei. Current advances and development of bio-butanol separation techniques [J]. Chemical Industry and Engineering Progress, 2021, 40(3): 1161-1177.
[14]	ZHOU Zikang, XU Ping. Application and progress of global transcription regulation in microbial cell factory construction [J]. Chemical Industry and Engineering Progress, 2021, 40(3): 1248-1251.
[15]	GUO Liang, GAO Cong, ZHANG Li, CHEN Xiulai, LIU Liming. Advances in the suitability of artificial metabolic pathways [J]. Chemical Industry and Engineering Progress, 2021, 40(3): 1252-1261.